Study of Adjunctive Ganaxolone Treatment in Children and Young Adults With CDKL5 Deficiency Disorder

PHASE3CompletedINTERVENTIONAL
Enrollment

101

Participants

Timeline

Start Date

June 30, 2018

Primary Completion Date

July 31, 2020

Study Completion Date

May 28, 2021

Conditions
CDKL5 Deficiency Disorder
Interventions
DRUG

ganaxolone

active drug

DRUG

Placebo

inactive

Trial Locations (36)

3084

Marinus Research Site, Heidelberg

3168

Marinus Research Site, Melbourne

4101

Marinus Research Site, Brisbane

15224

Marinus Research Site, Pittsburgh

30093

Marinus Research Site, Norcross

32561

Marinus Research Site, Gulf Breeze

32819

Marinus Research Site, Orlando

44195

Marinus Research Site, Cleveland

52242

Marinus Research Site, Iowa City

55905

Marinus Research Site, Rochester

63130

Marinus Research Site, St Louis

76104

Marinus Research Site, Fort Worth

77030

Marinus Research Site, Houston

80045

Marinus Research Site, Aurora

85016

Marinus Research Site, Phoenix

90095-1742

Marinus Research Site, Los Angeles

60612-3852

Marinus Research Site, Chicago

02115

Marinus Research Site, Boston

07039

Marinus Research Site, Livingston

19104-4318

Marinus Research Site, Philadelphia

Unknown

Marinus Research Site, Paris

Marinus Research Site, Ramat Gan

Marinus Research Site, Florence

Marinus Research Site, Milan

Marinus Research Site, Pavia

Marinus Research Site, Roma

Marinus Research Site, Verona

Marinus Research Site, Bydgoszcz

Marinus Research Site, Krakow

Marinus Research Site, Moscow

Marinus Research Site, Nizhny Novgorod

Marinus Research Site, Novosibirsk

Marinus Research Site, Birmingham

Marinus Research Site, Bristol

Marinus Research Facility, Glasgow

Marinus Research Site, London

Sponsors
All Listed Sponsors
lead

Marinus Pharmaceuticals

INDUSTRY

NCT03572933 - Study of Adjunctive Ganaxolone Treatment in Children and Young Adults With CDKL5 Deficiency Disorder | Biotech Hunter | Biotech Hunter